Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 5, pp 311–315 | Cite as

A drug use review study in patients with obstructive lung disease

Assessment of the quality of drug therapy
  • G. Van den Brink
  • C. W. Bollen
  • O. E. M. Van de Wall
  • L. J. J. Hoeve
  • A. J. Porsius
Articles

Abstract

This study presents the results of an analysis of the pharmacy records of 778 patients with asthma or chronic obstructive lung diseases. The high percentage of patients taking oral corticosteroids was striking. Inhaledβ-agonists for use as needed have been prescribed to only a minority of patients using these agents. Only half of the patients onβ-agonists used inhaled corticosteroids prophylactically. Drug interactions capable of causing changes in plasma theophylline concentrations appeared in only a small number of patients. The results from studies like the one presented here can provide valuable data to be used for further discussion between physicians and pharmacists about rational drug therapy.

Keywords

Adrenal cortex hormones Adrenergic beta receptor agonists Adrenergic beta receptor blockaders Contra-indications Dosage regimens Drug interactions Drug therapy Drug utilization Lung diseases, obstructive Quality control 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989;321:1517–27.PubMedGoogle Scholar
  2. 2.
    Barnes PJ. Chung KF. Difficult asthma — cause for concern. BMJ 1989;299:695–8.PubMedGoogle Scholar
  3. 3.
    Model M, Harding JM, Horder E, Williams PR. Improving the care of asthmatic patients in general practice. BMJ 1983;286:2027–30.PubMedGoogle Scholar
  4. 4.
    Nicklas RA. Perspective on asthma mortality 1989. Ann Allergy 1989;63:578–84.PubMedGoogle Scholar
  5. 5.
    Dieleman FE, Dekker FW, Kaptein AA. Compliantie bij astmamedicatie [Compliance in asthma medication]. Huisarts Wetensch 1989;32:43–7.Google Scholar
  6. 6.
    Horn CR. Cochrane GM. Management of asthma in general practice. Respir Med 1989;83:67–70.PubMedGoogle Scholar
  7. 7.
    Rucker TD. Pursuing rational drug therapy: a macro view a la the USA. J Soc Admin Pharm 1988;5:78–86.Google Scholar
  8. 8.
    Ferguson JA. Drug prescribing habits related to characteristics of medical practice. J Soc Admin Pharm 1990;7:34–47.Google Scholar
  9. 9.
    Van den Brink G, Sjoukes F, Wittop Koning PA, Porsius AJ. Medicamenteuze therapie van patiënten die organische nitraten gebruiken [Drug use in patients taking organic nitrates]. Pharm Weekbl 1990;125:898–902.Google Scholar
  10. 10.
    Leufkens HGM. Pharmacy records in pharmaco-epidemiology. Studies on antiinflammatory and antirheumatic drugs [dissertation]. Utrecht: Univ of Utrecht, 1990.Google Scholar
  11. 11.
    Cott GR, Cherniack RM. Steroids and “steroid-sparing” agents in asthma. N Engl J Med 1988;318:634–6.PubMedGoogle Scholar
  12. 12.
    Woolcock AJ, Salome CM, Keena VA. Therapy for bronchial hyperreactivity-reducing the severity of bronchial hyperresponsiveness. Ann Rev Respir Dis 1991;143:S75–7.Google Scholar
  13. 13.
    Sears MR, Taylor DR, Print CG, Lake DC, Li Q, Flannery AM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Van Schayck CP, Dompeling E, Van Herwaarden CLA, Folgering H, Verbeek ALM, Van der Hoogen JM, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991;303:1426–31.PubMedGoogle Scholar
  15. 15.
    Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta-2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388–92.PubMedGoogle Scholar
  16. 16.
    Rees J.β 2-Agonists and asthma-still the mainstay of symptomatic treatment. BMJ 1991;302:1166–7.PubMedGoogle Scholar
  17. 17.
    Addis GJ. Theophylline in the management of airflow obstruction — much evidence suggest that theophylline is valuable. BMJ 1990;300:928–9.PubMedGoogle Scholar
  18. 18.
    Johnston IDA. Theophylline in the management of airflow obstruction — difficult drugs to use, few clinical indications. BMJ 1990;300:929–31.PubMedGoogle Scholar
  19. 19.
    Hansten PD, Horn JR. Drug interactions — clinical significance of drug-drug interactions. 6th ed. Philadelphia: Lea & Febiger, 1989.Google Scholar
  20. 20.
    Boehning W. Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airway disease treated with theophylline and corticosteroids. Eur J Clin Pharmacol 1990;38:43–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Verdiani P, DiCarlo S, Baronti A. Famotidine effects on theophylline pharmacokinetics in subjects affected with COPD-comparison with cimetidine and placebo. Chest 1988;94:807–10.PubMedGoogle Scholar
  22. 22.
    Kendall MJ. Impact of beta1 selectivity and intrinsic sympathomimetic activity on potential unwanted non-cardiovascular effects of beta blockers. Am J Cardiol 1987;59:44F-7F.CrossRefPubMedGoogle Scholar
  23. 23.
    Frishman WH. Clinical significance of beta1 selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug. Am J Cardiol 1987;59:33F-7F.CrossRefPubMedGoogle Scholar
  24. 24.
    Kelly HW. Drug-induced pulmonary disorders. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics — the clinical use of drugs. 4th ed. Washington: Applied Therapeutics, 1988:437–45.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • G. Van den Brink
    • 1
  • C. W. Bollen
    • 1
  • O. E. M. Van de Wall
    • 1
  • L. J. J. Hoeve
    • 2
  • A. J. Porsius
    • 1
  1. 1.Department of PharmacotherapyUniversity of UtrechtTB UtrechtThe Netherlands
  2. 2.Health Fund Pharmacy “Ziekenzorg,”GH UtrechtThe Netherlands

Personalised recommendations